Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 25 peer-reviewed journal articles Updated
Oncology

The Long View: Survivorship and Life After RCC

At a Glance

After completing treatment for renal cell carcinoma (RCC), long-term survivorship focuses on two critical areas: regular imaging scans to monitor for cancer recurrence, and strictly controlling blood pressure to protect your remaining kidney function.

The completion of treatment for Renal Cell Carcinoma (RCC) marks the beginning of a new phase: survivorship. While the immediate threat of the tumor has been addressed, this period involves a long-term commitment to monitoring for recurrence and protecting your remaining kidney function [1][2].

Monitoring for Recurrence: The Roadmap

Surveillance is not “one-size-fits-all.” Your schedule of scans will be tailored based on your risk stratification—a score calculated by your doctors using your tumor’s size, stage, and grade (such as the Leibovich or UISS scores) [1][3].

  • Imaging Modality: Computed Tomography (CT) of the chest and abdomen is the standard tool because of its high sensitivity in detecting early changes [4][5]. MRI may be used if you need to limit radiation exposure or if a specific area needs closer inspection [1].
  • The Safety of IV Contrast: A common worry for patients with a single kidney is whether the IV contrast dye used in CT scans will damage their remaining kidney. Modern medical protocols and newer contrast agents are very safe. Your care team will ensure you are properly hydrated and will monitor your kidney function (eGFR) closely to safely administer these essential scans.
  • The First Five Years: Most recurrences (~75%) happen within the first five years [1]. Consequently, imaging is most frequent during the first 2–3 years, often occurring every 3 to 6 months for high-risk patients [3][6].
  • Long-Term Follow-Up: Because kidney cancer can occasionally return more than a decade later, many experts recommend extended monitoring, potentially for life, depending on your initial risk level [7][8].

Protecting Your “Solitary” Kidney

Whether you had a partial nephrectomy (preserving part of the kidney) or a radical nephrectomy (removing the entire kidney), your remaining kidney tissue is now working harder [9][10].

To prevent Chronic Kidney Disease (CKD), you must act as a guardian for your remaining nephrons (the filtering units of the kidney) [11][12]:

  1. Blood Pressure Control: This is the single most important factor. High blood pressure acts like a “pressure cooker” on the remaining kidney filters. Maintaining a healthy BP (often through a class of drugs called RAS blockers) is essential [13][14].
  2. Avoid Nephrotoxic Drugs: Non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen or naproxen can be toxic to the kidneys and should generally be avoided [2][15]. Always check with your doctor before starting any new medication.
  3. Manage Comorbidities: Conditions like diabetes can accelerate kidney damage. Managing blood sugar is vital for long-term renal health [16][17].
  4. Hydration and Diet: While strict protein restriction is not always required for everyone, maintaining a heart-healthy diet and steady hydration supports overall kidney function [18][19].

Navigating “Scanxiety”

The emotional toll of chronic monitoring is real and has a name: scanxiety. This refers to the distress that often peaks in the days leading up to an imaging appointment and while awaiting results [20][21].

Research shows that over 70% of cancer survivors experience this phenomenon, which can manifest as irritability, sleep loss, or a feeling like the “Sword of Damocles” is hanging over them [20][22].

  • Acknowledge the feeling: Understanding that this is a recognized medical phenomenon can help you feel less “alone” in your anxiety [20].
  • Communication: Talk to your team about how and when results will be delivered. Knowing the timeline can reduce the agony of the wait [23].
  • Quality of Life: Long-term survivors of RCC can live full, active lives. Prioritizing your mental health is as important as your physical check-ups [24][25].

Common questions in this guide

How often will I need scans after RCC treatment?
Your scan schedule depends on your specific risk for recurrence, which is based on the tumor's size, stage, and grade. High-risk patients typically have CT scans every 3 to 6 months during the first few years, when recurrence is most likely.
Is the IV contrast dye used in CT scans safe for my remaining kidney?
Modern contrast dyes used in CT scans are generally very safe for patients with one kidney. Your care team will monitor your kidney function levels and ensure you are properly hydrated to protect your kidney during these essential imaging tests.
What medications should I avoid to protect my remaining kidney?
You should generally avoid non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen and naproxen, as they can be toxic to the kidneys. Always check with your healthcare provider before taking any new over-the-counter medications or supplements.
How can I prevent kidney damage after a partial or radical nephrectomy?
The most critical step in protecting your remaining kidney is maintaining healthy blood pressure, as high blood pressure puts extra stress on kidney filters. You should also stay well-hydrated, manage conditions like diabetes, and eat a heart-healthy diet.
What is scanxiety and how can I cope with it?
Scanxiety is the emotional distress patients feel leading up to cancer imaging appointments and while waiting for results. It is a highly common phenomenon. You can manage it by acknowledging your feelings, communicating with your doctor about when to expect results, and prioritizing your mental health.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my tumor’s stage and grade, am I considered low, intermediate, or high risk for recurrence?
  2. 2.What is my current eGFR (kidney function) level, and how has it changed since my surgery?
  3. 3.Are there specific blood pressure targets I should aim for to protect my remaining kidney tissue?
  4. 4.Which medications (like certain over-the-counter pain relievers) should I strictly avoid to prevent kidney damage?
  5. 5.How long can I expect to wait for my scan results, and who will contact me to discuss them?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (25)
  1. 1

    Surveillance following surgery for nonmetastatic renal cell carcinoma.

    Richards KA, Abel EJ

    Current opinion in urology 2016; (26(5)):432-8 doi:10.1097/MOU.0000000000000308.

    PMID: 27467135
  2. 2

    Renal cell carcinoma for the nephrologist.

    Perazella MA, Dreicer R, Rosner MH

    Kidney international 2018; (94(3)):471-483 doi:10.1016/j.kint.2018.01.023.

    PMID: 29661544
  3. 3

    [Follow-up of renal cell carcinoma based on stage and initial treatment].

    Doehn C, Siebels M, Steiner T

    Der Urologe. Ausg. A 2020; (59(2)):162-168 doi:10.1007/s00120-020-01126-8.

    PMID: 32047953
  4. 4

    Role of F-18 FDG PET/CT in the follow-up of asymptomatic renal cell carcinoma patients for postoperative surveillance: based on conditional survival analysis.

    Park S, Lee HY, Lee S

    Journal of cancer research and clinical oncology 2022; (148(1)):215-224 doi:10.1007/s00432-021-03688-2.

    PMID: 34106327
  5. 5

    Nurse-led renal cell carcinoma clinic: a single center review.

    Thia I, Tan A, Botha E, et al.

    ANZ journal of surgery 2024; (94(6)):1071-1075 doi:10.1111/ans.18920.

    PMID: 38426382
  6. 6

    Optimal Surveillance Strategies After Surgery for Renal Cell Carcinoma.

    Tyson MD, Chang SS

    Journal of the National Comprehensive Cancer Network : JNCCN 2017; (15(6)):835-840 doi:10.6004/jnccn.2017.0102.

    PMID: 28596262
  7. 7

    Incidence and Pattern of Recurrence after Surgical Resection in Organ-Confined Renal Cell Carcinoma.

    Kim J, Ham WS, Park JS, Jang WS

    Yonsei medical journal 2024; (65(11)):623-628 doi:10.3349/ymj.2023.0587.

    PMID: 39439165
  8. 8

    A clinical investigation of recurrence and lost follow-up after renal cell carcinoma surgery: a single-center, long-term, large cohort, retrospective study.

    Arai T, Sazuka T, Sato H, et al.

    International journal of clinical oncology 2022; (27(9)):1467-1476 doi:10.1007/s10147-022-02204-x.

    PMID: 35767079
  9. 9

    A clinical audit of adverse post-nephrectomy outcomes in renal cell carcinoma patients at a tertiary hospital in Queensland, Australia.

    de Souza JC, Vangaveti V, Biros E, Mallett AJ

    Journal of nephrology 2025; (38(5)):1357-1368 doi:10.1007/s40620-024-02173-6.

    PMID: 39762514
  10. 10

    Partial nephrectomy for T1 renal cancer can achieve an equivalent oncological outcome to radical nephrectomy with better renal preservation: the way to go.

    Lai TC, Ma WK, Yiu MK

    Hong Kong medical journal = Xianggang yi xue za zhi 2016; (22(1)):39-45 doi:10.12809/hkmj144482.

    PMID: 26492927
  11. 11

    Chronic Kidney Disease in Cancer Survivors.

    Lee M, Wang Q, Wanchoo R, et al.

    Advances in chronic kidney disease 2021; (28(5)):469-476.e1 doi:10.1053/j.ackd.2021.10.007.

    PMID: 35190113
  12. 12

    End-stage renal disease after renal cancer surgery: risk factors and overall survival.

    Åkerlund J, Ljungberg B, Lundstam S, et al.

    Scandinavian journal of urology 2024; (59()):109-116 doi:10.2340/sju.v59.40322.

    PMID: 38747153
  13. 13

    Renal Outcomes With Renin-Angiotensin System Blockers After Unilateral Nephrectomy.

    Lee S, Yoon S, Kim S, et al.

    Kidney international reports 2025; (10(1)):184-196 doi:10.1016/j.ekir.2024.09.022.

    PMID: 39810785
  14. 14

    Do children with solitary or hypofunctioning kidney have the same prevalence for masked hypertension?

    Yel S, Günay N, Pınarbaşı AS, et al.

    Pediatric nephrology (Berlin, Germany) 2021; (36(7)):1833-1841 doi:10.1007/s00467-020-04896-7.

    PMID: 33459937
  15. 15

    Management and optimization of chronic renal insufficiency in the setting of kidney cancer A Systematic Review.

    Cobb JK, Miyagi H, Chahoud J, et al.

    International braz j urol : official journal of the Brazilian Society of Urology 2025; (51(5)).

    PMID: 40658472
  16. 16

    Renal functional outcomes after nephrectomy in patients with localized renal cell carcinoma and diabetes mellitus: a systematic review and meta-analysis.

    Yang Y, Meng L, Hu X, Li X

    International urology and nephrology 2024; (56(6)):1859-1868 doi:10.1007/s11255-023-03885-7.

    PMID: 38300449
  17. 17

    The impact of T1 renal tumor characteristics on baseline renal function in patients undergoing partial nephrectomy: A renal scan based objective assessment.

    Porpiglia F, Autorino R, Fiori C, et al.

    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2017; (43(8)):1598-1602 doi:10.1016/j.ejso.2017.05.017.

    PMID: 28579358
  18. 18

    Diabetes Remission After Radical Nephrectomy in a Geriatric Patient With Obesity and Type 2 Diabetes-34 Months' Follow-Up.

    Tripathi P, Kadam N, Sharma B, et al.

    JCEM case reports 2024; (2(12)):luae210 doi:10.1210/jcemcr/luae210.

    PMID: 39544889
  19. 19

    Identifying risk factors for chronic kidney disease stage 3 in adults with acquired solitary kidney from unilateral nephrectomy: a retrospective cohort study.

    Zhang WJ, Wang ZY, Zhou WX, et al.

    BMC nephrology 2020; (21(1)):397 doi:10.1186/s12882-020-02059-2.

    PMID: 32928128
  20. 20

    Prevalence, severity, and modifiable predictors of scanxiety in patients undergoing routine oncologic imaging: a prospective longitudinal study.

    Shah MS, Memon JA, Malik U, et al.

    Clinical imaging 2025; (128()):110634 doi:10.1016/j.clinimag.2025.110634.

    PMID: 41077027
  21. 21

    Scanxiety among Adults with Cancer: A Scoping Review to Guide Research and Interventions.

    Derry-Vick HM, Heathcote LC, Glesby N, et al.

    Cancers 2023; (15(5)) doi:10.3390/cancers15051381.

    PMID: 36900174
  22. 22

    Scan-Associated Distress in People Affected by Cancer: A Qualitative Systematic Review.

    Hussain M, Chau S, Turner M, Paterson C

    Seminars in oncology nursing 2023; (39(5)):151502 doi:10.1016/j.soncn.2023.151502.

    PMID: 37735038
  23. 23

    Prevalence and severity of scanxiety in people with advanced cancers: a multicentre survey.

    Bui KT, Kiely BE, Dhillon HM, et al.

    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2022; (30(1)):511-519 doi:10.1007/s00520-021-06454-9.

    PMID: 34333717
  24. 24

    Scanxiety and quality of life around follow-up imaging in patients with unruptured intracranial aneurysms: a prospective cohort study.

    Kamphuis MJ, van der Kamp LT, van Eijk RPA, et al.

    European radiology 2024; (34(9)):6018-6025 doi:10.1007/s00330-024-10602-0.

    PMID: 38311702
  25. 25

    Quality of life assessment in renal cell carcinoma Phase II and III clinical trials published between 2010 and 2020: a systematic review.

    Rizzo A, Mollica V, Dall'Olio FG, et al.

    Future oncology (London, England) 2021; (17(20)):2671-2681 doi:10.2217/fon-2021-0069.

    PMID: 33880963

This page provides educational information on survivorship and life after renal cell carcinoma treatment. Always consult your oncologist or urologist for personalized follow-up care and kidney monitoring.

Get notified when new evidence is published on Renal cell carcinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.